The following is a summary of the Ekso Bionics Holdings, Inc. (EKSO) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Ekso Bionics reported a Q1 2024 revenue of $3.8 million, a slight decrease from Q1 2023's revenue of $4.1 million.

• The company saw an increase in gross margin to 52% in Q1 2024, up from 49% in Q1 2023, primarily due to the lower EksoHealth device and service costs.

• They also successfully reduced their operating expenses by 19%, falling to $5.2 million in Q1 2024 from $6.4 million in Q1 2023, largely due to decreased administrative expenses.

• The net loss in Q1 2024 was lower with a loss of $3.4 million ($0.20 per share) compared to a loss of $4.4 million ($0.33 per share) in Q1 2023.

Business Progress:

• Ekso Bionics sold a total of 29 EksoHealth devices in Q1 2024, influenced mildly by the onset of seasonality.

• The final payment determination for Medicare reimbursement for the company's Indego Personal device has been confirmed, allowing them to target clinical, home, and community settings as well as potential Medicare and Medicaid-covered individuals with spinal cord injuries.

• Ekso is planning to expand by establishing more certified training centers all over the US.

• The interest in Ekso Bionics in the international market, especially in the EMEA region, is steadily rising.

• The sales in Ekso's Industrial segment, EksoWorks, saw a remarkable increase of nearly 60% in Q1 2024 from Q1 2023.

• With the established reimbursement pricing for the Ekso Indego Personal by CMS, Ekso Bionics looks forward to driving growth.

More details: Ekso Bionics Holdings, Inc. IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.